Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)
Historic Receivables - Other for Cartesian Therapeutics (RNAC) over the last 5 years, with Q3 2024 value amounting to $980000.0.
- Cartesian Therapeutics' Receivables - Other fell 4773.33% to $980000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $980000.0, marking a year-over-year decrease of 4773.33%. This contributed to the annual value of $3.0 million for FY2023, which is 572.42% down from last year.
- Per Cartesian Therapeutics' latest filing, its Receivables - Other stood at $980000.0 for Q3 2024, which was down 4773.33% from $3.5 million recorded in Q2 2024.
- Cartesian Therapeutics' 5-year Receivables - Other high stood at $3.5 million for Q2 2024, and its period low was $980000.0 during Q3 2024.
- Moreover, its 5-year median value for Receivables - Other was $1.5 million (2020), whereas its average is $1.8 million.
- Data for Cartesian Therapeutics' Receivables - Other shows a peak YoY increase of 22909.95% (in 2024) and a maximum YoY decrease of 4773.33% (in 2024) over the last 5 years.
- Over the past 5 years, Cartesian Therapeutics' Receivables - Other (Quarter) stood at $1.4 million in 2020, then fell by 28.57% to $1.0 million in 2021, then soared by 216.2% to $3.2 million in 2022, then fell by 5.72% to $3.0 million in 2023, then tumbled by 67.13% to $980000.0 in 2024.
- Its Receivables - Other was $980000.0 in Q3 2024, compared to $3.5 million in Q2 2024 and $2.4 million in Q1 2024.